Millions of people are now successfully using hormone antagonists for the treatment of endocrine-dependent cancers. In Hormone Therapy in Breast and Prostate Cancer, many of today's leading researchers and clinicians describe the principles underlying these targeted treatments, assess the actions of new and established agents, and illustrate the new applications of hormonal chemoprevention for breast cancer. Topics range from preclinical and clinical antiestrogens to the inhibition of estrogen synthesis and the effects of androgen withdrawal. A wide variety of proven and new agents are discussed-antiestrogens, including aromatase inhibitors (anastrozole, letrozole, and others), SERMs (tamoxifen, raloxifene, and others), and such antiandrogenic strategies as goserelin and bicalutamide.
Unique in its synthesis, Hormone Therapy in Breast and Prostate Cancer offers medical and surgical oncologists, urologists, physicians, and clinical pharmacologists a sound basis for understanding targeted treatments of breast and prostate cancers, and provides a well-proven model for developing powerful new cancer therapeutics.